Kintara Therapeutics Inc
NASDAQ:KTRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kintara Therapeutics Inc
NASDAQ:KTRA
|
US |
|
Hainan Shuangcheng Pharmaceuticals Co Ltd
SZSE:002693
|
CN |
|
Hangzhou DPtech Technologies Co Ltd
SZSE:300768
|
CN |
|
Gujarat Alkalies And Chemicals Ltd
NSE:GUJALKALI
|
IN |
|
P
|
Pricer AB
STO:PRIC B
|
SE |
|
Shivam Autotech Ltd
NSE:SHIVAMAUTO
|
IN |
|
S
|
STMicroelectronics NV
XETRA:SGM
|
CH |
|
A
|
Adventa Bhd
KLSE:ADVENTA
|
MY |
|
Shenzhen Sunshine Laser & Electronics Technology Co Ltd
SZSE:300227
|
CN |
|
H
|
Halmont Properties Corp
XTSX:HMT
|
CA |
|
Volvo Car AB
STO:VOLCAR B
|
SE |
|
C
|
Chagee Holdings Ltd
NASDAQ:CHA
|
CN |
|
Energean PLC
LSE:ENOG
|
UK |
Kintara Therapeutics Inc
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2016-07-12. The firm is developing two late-stage, Phase III-ready therapeutics. The firm's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The firm is carrying out various clinical trials on brain tumor and solid tumor.
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2016-07-12. The firm is developing two late-stage, Phase III-ready therapeutics. The firm's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The firm is carrying out various clinical trials on brain tumor and solid tumor.
